824 filings
Page 4 of 42
8-K
y89foi2666 pov
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
rodaxwj3e42o
19 Apr 23
Correspondence with SEC
12:00am
8-K
dsppxj9de2 k50w1h
14 Apr 23
Other Events
8:33am
8-K
3lqrhsmci6r64nu0d
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
UPLOAD
1yge18 yyh3ftzudk
7 Apr 23
Letter from SEC
12:00am
8-K
f1k4d7z
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
0nmddo5e uqth
14 Feb 23
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
7:46am
8-K
60izisx dtsn
9 Feb 23
Soligenix Announces Reverse Stock Split
7:45am
DEFA14A
uc6f00l3 x6a
11 Jan 23
Additional proxy soliciting materials
8:02am
8-K
5pxw6opyy7mg
11 Jan 23
Other Events
8:00am
8-K
c0sv l9tnj8k3uth
27 Dec 22
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
4:25pm
8-A12G
lq6nlp f7f
27 Dec 22
Registration of securities
4:05pm
8-K
mst5v9vx
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
ciaeb78020t
19 Dec 22
Other Events
8:00am
8-K
k911chy lnxm11d8
15 Dec 22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
8:14am
8-K
ukt2 01kk
18 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:45pm